Nephros Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Nephros wird ein Gewinn- und Umsatzwachstum von 123.1% bzw. 6.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 121.3% pro Jahr wachsen soll.

Wichtige Informationen

125.8%

Wachstumsrate der Gewinne

124.7%

EPS-Wachstumsrate

Machinery Gewinnwachstum	8.2%
Wachstumsrate der Einnahmen	5.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	22 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their Estimates

May 13

Recent updates

It's A Story Of Risk Vs Reward With Nephros, Inc. (NASDAQ:NEPH)

Oct 03

We're Not Worried About Nephros' (NASDAQ:NEPH) Cash Burn

Jul 14

Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their Estimates

May 13

After Leaping 40% Nephros, Inc. (NASDAQ:NEPH) Shares Are Not Flying Under The Radar

Dec 18

At US$3.18, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?

Dec 14

Nephros partners with Donastar and Tractor Beverage to supply and service nationwide fast-casual restaurant operation

Sep 28

US$5.13: That's What Analysts Think Nephros, Inc. (NASDAQ:NEPH) Is Worth After Its Latest Results

Aug 13

Market Sentiment Around Loss-Making Nephros, Inc. (NASDAQ:NEPH)

Mar 25

At US$8.37, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?

Mar 04

Announcing: Nephros (NASDAQ:NEPH) Stock Increased An Energizing 131% In The Last Five Years

Jan 28

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:NEPH - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	15	0	N/A	N/A	1
12/31/2024	14	-1	N/A	N/A	2
6/30/2024	14	-1	-1	-1	N/A
3/31/2024	14	-1	0	0	N/A
12/31/2023	14	-2	1	1	N/A
9/30/2023	14	-2	1	1	N/A
6/30/2023	12	-3	0	0	N/A
3/31/2023	12	-3	-1	-1	N/A
12/31/2022	10	-5	-3	-3	N/A
9/30/2022	10	-5	-4	-3	N/A
6/30/2022	10	-4	-4	-4	N/A
3/31/2022	10	-4	-3	-3	N/A
12/31/2021	10	-3	-2	-1	N/A
9/30/2021	10	-3	-3	-3	N/A
6/30/2021	9	-4	-4	-4	N/A
3/31/2021	9	-4	-5	-5	N/A
12/31/2020	9	-5	-7	-7	N/A
9/30/2020	9	-4	-5	-5	N/A
6/30/2020	10	-4	-4	-4	N/A
3/31/2020	11	-3	-3	-3	N/A
12/31/2019	10	-3	-2	-2	N/A
9/30/2019	9	-4	-3	-3	N/A
6/30/2019	7	-4	-4	-4	N/A
3/31/2019	6	-3	-4	-4	N/A
12/31/2018	6	-3	-4	-4	N/A
9/30/2018	5	-1	-1	-1	N/A
6/30/2018	5	-1	-1	-1	N/A
3/31/2018	4	-2	N/A	0	N/A
12/31/2017	4	-1	N/A	0	N/A
9/30/2017	3	-3	N/A	-2	N/A
6/30/2017	3	-3	N/A	-2	N/A
3/31/2017	2	-3	N/A	-2	N/A
12/31/2016	2	-3	N/A	-2	N/A
9/30/2016	2	-3	N/A	-3	N/A
6/30/2016	2	-3	N/A	-3	N/A
3/31/2016	2	-4	N/A	-3	N/A
12/31/2015	2	-3	N/A	-4	N/A
9/30/2015	2	-3	N/A	-3	N/A
6/30/2015	2	0	N/A	-3	N/A
3/31/2015	2	-4	N/A	-3	N/A
12/31/2014	2	-7	N/A	-2	N/A
9/30/2014	2	-2	N/A	-3	N/A
6/30/2014	2	-6	N/A	-2	N/A
3/31/2014	2	-1	N/A	-3	N/A
12/31/2013	2	1	N/A	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NEPH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: NEPH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: NEPH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: NEPHDie Einnahmen des Unternehmens (6.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: NEPHDie Einnahmen des Unternehmens (6.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NEPH in 3 Jahren voraussichtlich hoch sein wird

Nephros Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus estimates of losses per share improve by 11%

Consensus EPS estimates upgraded to US$0.035 loss, revenue downgraded

Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their Estimates

Forecast to breakeven in 2025

Consensus EPS estimates upgraded to US$0.12 loss

Consensus estimates of losses per share improve by 30%

Recent updates

It's A Story Of Risk Vs Reward With Nephros, Inc. (NASDAQ:NEPH)

Consensus estimates of losses per share improve by 11%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Nephros, Inc. to Report Q2, 2024 Results on Aug 08, 2024

We're Not Worried About Nephros' (NASDAQ:NEPH) Cash Burn

President recently bought US$112k worth of stock

Consensus EPS estimates upgraded to US$0.035 loss, revenue downgraded

Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their Estimates

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2025

Nephros, Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Nephros, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Now 21% undervalued

Now 25% undervalued

After Leaping 40% Nephros, Inc. (NASDAQ:NEPH) Shares Are Not Flying Under The Radar

At US$3.18, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?

Consensus EPS estimates upgraded to US$0.12 loss

Consensus estimates of losses per share improve by 30%

Forecast to breakeven in 2025

Nephros, Inc., Hires Judy Krandel as Chief Financial Officer

Nephros, Inc., Hires Judy Krandel as Chief Financial Officer

Nephros, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Nephros, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Share price stability

No longer forecast to breakeven

First quarter 2023 earnings: EPS misses analyst expectations

Nephros, Inc. Announces CEO Changes

Forecast to breakeven in 2024

Consensus EPS estimates fall by 37%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased by 27% to US$3.00

Less than half of directors are independent

Nephros, Inc. Announces Board Changes

Nephros, Inc. to Report Q4, 2022 Results on Mar 08, 2023

Nephros, Inc. announced delayed 10-Q filing

Price target decreased to US$3.63

Consensus EPS estimates fall by 23%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Nephros, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Nephros partners with Donastar and Tractor Beverage to supply and service nationwide fast-casual restaurant operation

Nephros Appoints Joe Harris to Its Board of Directors

Wes Lobo, Chief Commercial Officer of Nephros, Inc. Resigns, to Be Effective No Later Than September 30, 2022

US$5.13: That's What Analysts Think Nephros, Inc. (NASDAQ:NEPH) Is Worth After Its Latest Results

Second quarter 2022 earnings: EPS exceeds analyst expectations

Nephros, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Nephros Receives FDA 510(k) Clearance for HDF Assist Module

Consensus revenue estimates fall by 17%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$9.33

Nephros, Inc., Annual General Meeting, May 19, 2022

Full year 2021 earnings: EPS misses analyst expectations

Nephros, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2022

Price target decreased to US$12.33

Nephros, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021 and for the Year 2022

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.12 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.19 loss in 2Q 2020)

Forecast to breakeven in 2023

No longer forecast to breakeven

Consensus revenue estimates fall to US$10.9m

First quarter 2021 earnings released: US$0.06 loss per share (vs US$0.14 loss in 1Q 2020)

Nephros, Inc. Provides Revenue Guidance for the Quarter Ended March 31, 2021

Market Sentiment Around Loss-Making Nephros, Inc. (NASDAQ:NEPH)

Analysts lower revenue estimates to US$11.5m

At US$8.37, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?